# DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants

> **NCT02094833** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 310 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Haemophilus Influenzae Type b Infection
- Poliomyelitis
- Hepatitis B

## Interventions

- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP~T combined vaccine
- **BIOLOGICAL:** DTaP-IPV//PRP~T and Hepatitis B vaccine

## Key facts

- **NCT ID:** NCT02094833
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-04
- **Final completion:** 2016-11
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094833, "DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02094833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*